Abbott Laboratories Declares Quarterly Dividend of $0.59 (NYSE:ABT)

Key Points

• Abbott Laboratories declared a quarterly dividend of $0.59 per share, with an annual yield of 1.8%, payable on November 17th to investors of record on October 15th.
• The company reported $1.26 earnings per share for the last quarter, meeting analysts' expectations and reflecting a 7.4% increase in revenue year-over-year.
• Analysts maintain a Moderate Buy rating for Abbott Laboratories, with a consensus price target of $145.22 and significant upgrades from firms like William Blair and Evercore ISI.

Abbott Laboratories (NYSE:ABT - Get Free Report) announced a quarterly dividend on Friday, September 19th, RTT News reports. Investors of record on Wednesday, October 15th will be given a dividend of 0.59 per share by the healthcare product maker on Monday, November 17th. This represents a c) dividend on an annualized basis and a yield of 1.8%.

Abbott Laboratories has a dividend payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Abbott Laboratories to earn $5.73 per share next year, which means the company should continue to be able to cover its $2.36 annual dividend with an expected future payout ratio of 41.2%.

Abbott Laboratories Trading Down 0.1%

Shares of Abbott Laboratories stock opened at $134.10 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market cap of $233.39 billion, a PE ratio of 16.85, a P/E/G ratio of 2.54 and a beta of 0.69. The business's fifty day moving average is $130.38 and its two-hundred day moving average is $131.20. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 EPS. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ABT. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Raymond James Financial lowered their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Finally, Evercore ISI increased their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $145.22.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.